News und Analysen

Image source: The Motley Fool.

Biogen (NASDAQ: BIIB)Q4 2023 Earnings CallFeb 13, 2024, 8:00 a.m. ET

Operator

Continue reading

Source Fool.com

It is customary to say that past success isn't a guarantee that a company will continue down that path -- a true statement. However, a corporation's track record provides vital information about its

It is customary to say that past success isn't a guarantee that a company will continue down that path -- a true statement. However, a corporation's track record provides vital information about its

It is customary to say that past success isn't a guarantee that a company will continue down that path -- a true statement. However, a corporation's track record provides vital information about its

The stock market is on fire as 2024 kicks off. As a result, many investors might be reviewing their long-term financial goals as well as their plans for stock purchases. As always, it's best to

The stock market is on fire as 2024 kicks off. As a result, many investors might be reviewing their long-term financial goals as well as their plans for stock purchases. As always, it's best to

There are thousands of drugs on the market, and there are thousands more that are no longer in use. However, none has been more successful in terms of sales than AbbVie's (NYSE: ABBV) Humira. That's

Stocks across a range of sectors have been feeling the market volatility over the last few years. Even as stocks have rebounded considerably in recent months -- the S&P 500 is trading up by around

Stocks across a range of sectors have been feeling the market volatility over the last few years. Even as stocks have rebounded considerably in recent months -- the S&P 500 is trading up by around

In biotech, it's often difficult to tell whether bad news for one company will also be bad news for a competitor, or vice versa. Between using different approaches to therapy development, working

Vertex Pharmaceuticals (NASDAQ: VRTX) has been one of the hottest growth stocks to own within the healthcare industry. The company has a dominant cystic fibrosis (CF) business, and it has been

Vertex Pharmaceuticals (NASDAQ: VRTX) has been one of the hottest growth stocks to own within the healthcare industry. The company has a dominant cystic fibrosis (CF) business, and it has been

Vertex Pharmaceuticals (NASDAQ: VRTX) has been one of the hottest growth stocks to own within the healthcare industry. The company has a dominant cystic fibrosis (CF) business, and it has been

Investing in healthcare stocks can be a fantastic way to diversify your portfolio with businesses that generate steady growth in a wide range of market environments. Not all healthcare stocks are

Investing in healthcare stocks can be a fantastic way to diversify your portfolio with businesses that generate steady growth in a wide range of market environments. Not all healthcare stocks are

Investing in healthcare stocks can be a fantastic way to diversify your portfolio with businesses that generate steady growth in a wide range of market environments. Not all healthcare stocks are

Arguably the most important quality for any stock is whether or not it beats the market. If it doesn't, you'd be better off putting your money in an index fund.

Three Motley Fool contributors think

Arguably the most important quality for any stock is whether or not it beats the market. If it doesn't, you'd be better off putting your money in an index fund.

Three Motley Fool contributors think

Arguably the most important quality for any stock is whether or not it beats the market. If it doesn't, you'd be better off putting your money in an index fund.

Three Motley Fool contributors think

Vertex Pharmaceuticals (NASDAQ: VRTX) soared 85% over the past two years as it headed into a new era of growth. The company already has been a giant in the area of cystic fibrosis (CF) treatment for

Vertex Pharmaceuticals (NASDAQ: VRTX) soared 85% over the past two years as it headed into a new era of growth. The company already has been a giant in the area of cystic fibrosis (CF) treatment for

Vertex Pharmaceuticals (NASDAQ: VRTX) soared 85% over the past two years as it headed into a new era of growth. The company already has been a giant in the area of cystic fibrosis (CF) treatment for

Diabetes and weight-loss medicines surged in popularity last year. Few garnered nearly as much attention as Ozempic, a therapy marketed by Denmark-based biotech giant Novo Nordisk. Ozempic addresses

Diabetes and weight-loss medicines surged in popularity last year. Few garnered nearly as much attention as Ozempic, a therapy marketed by Denmark-based biotech giant Novo Nordisk. Ozempic addresses

Diabetes and weight-loss medicines surged in popularity last year. Few garnered nearly as much attention as Ozempic, a therapy marketed by Denmark-based biotech giant Novo Nordisk. Ozempic addresses